Analysts Set Affimed (NASDAQ:AFMD) PT at $45.00

Shares of Affimed (NASDAQ:AFMD) have been assigned an average rating of “Buy” from the five analysts that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued a report on the stock in the last year is $45.00.

AFMD has been the topic of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, April 1st. HC Wainwright raised their price target on Affimed to $10.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Finally, Wells Fargo & Company reduced their price objective on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, April 1st.

Hedge Funds Weigh In On Affimed

A number of hedge funds and other institutional investors have recently made changes to their positions in AFMD. Vestal Point Capital LP acquired a new stake in Affimed during the 4th quarter worth approximately $341,000. BNP Paribas Financial Markets raised its stake in shares of Affimed by 39.9% during the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares during the last quarter. EWA LLC purchased a new stake in shares of Affimed during the fourth quarter worth approximately $89,000. Finally, abrdn plc acquired a new stake in shares of Affimed during the fourth quarter worth $130,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $5.23 on Monday. The business’s 50 day moving average price is $5.42 and its 200-day moving average price is $5.09. Affimed has a 1 year low of $2.23 and a 1 year high of $11.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.25 and a quick ratio of 3.23. The firm has a market capitalization of $79.65 million, a PE ratio of -0.62 and a beta of 2.05.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.